Interferon therapy in chronic hepatitis C virus infection

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis C virus (HCV) infection is a significant global health concern.
• Interferon-based antiviral therapy has been a cornerstone treatment for HCV.
• Understanding treatment response and predictors is crucial for optimizing patient outcomes.

Purpose of the Study:

• To review the efficacy and outcomes of interferon treatment for chronic hepatitis C.
• To identify factors predicting treatment response and relapse.
• To discuss future therapeutic options for non-responders.

Main Methods:

• Review of existing literature on interferon treatment for chronic hepatitis C.
• Analysis of response rates, relapse rates, and sustained virologic response.
• Identification of patient and viral factors associated with treatment outcomes.

Main Results:

• Interferon therapy (≥3 MU t.i.w. for 6-12 months) achieves normal ALT levels in 50-60% of patients.
• Relapse occurs in approximately 50% of complete responders after treatment cessation.
• Longer treatment durations (12 vs. 6 months) reduce relapse rates and increase sustained response.
• Predictive factors for favorable response include low baseline HCV RNA, non-II genotypes, shorter disease duration, female gender, and less liver damage.
• Sustained responders show improved liver histology, including reduced inflammation and fibrosis.
• Non-responders or those with non-sustained responses often have persistent viremia.

Conclusions:

• Interferon therapy is effective in a significant proportion of chronic hepatitis C patients, but relapse is common.
• Treatment duration and patient-specific factors influence sustained virologic response.
• Ribavirin, particularly in combination with interferon, represents a promising therapeutic strategy for patients who do not respond adequately to interferon alone.